David Currow, BMed, PhD, MPH, FRACP, FAChPM, FAHMS, GAICD of Flinders University, Adelaide, Australia, discusses anamorelin in ROMANA 1 and ROMANA 2 studies. Anamorelin acts as a selective ghrelin receptor agonist and has a potential to increase lean body mass, appetite, and fat mass in people with cancer cachexia. Dr Currow highlights the 24-week follow-up data from ROMANA studies showing increase in lean body mass and fat mass, and decrease in anorexia, which was maintained in the anamorelin-treated study arm. Cachexia is one of the prognostic factors in cancer and Dr Currow sees this as a tremendous opportunity to open a new therapeutic corridor, which allows us to treat cachexia alongside the disease. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) 2016 Annual Congress in Adelaide, Australia.
Treating cachecia with anamorelin: 24-week follow-up data from ROMANA studies
